• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From data to practice: The necessity of optimizing ustekinumab treatment strategies.

作者信息

Wang FaYuan, He Ping

机构信息

College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou City, Sichuan Province, China.

College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou City, Sichuan Province, China.

出版信息

Dig Liver Dis. 2025 Jun;57(6):1335. doi: 10.1016/j.dld.2025.02.022. Epub 2025 Mar 9.

DOI:10.1016/j.dld.2025.02.022
PMID:40059031
Abstract
摘要

相似文献

1
From data to practice: The necessity of optimizing ustekinumab treatment strategies.从数据到实践：优化优特克单抗治疗策略的必要性。
Dig Liver Dis. 2025 Jun;57(6):1335. doi: 10.1016/j.dld.2025.02.022. Epub 2025 Mar 9.
2
Author's Reply: "From Data to practice: The necessity of optimizing ustekinumab treatment strategies".
Dig Liver Dis. 2025 Jun;57(6):1336-1337. doi: 10.1016/j.dld.2025.03.020. Epub 2025 Apr 5.
3
Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach.基于集成生物信息学方法探究乌司奴单抗治疗溃疡性结肠炎的疗效预测。
Int J Mol Sci. 2024 May 18;25(10):5532. doi: 10.3390/ijms25105532.
4
The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States.优特克单抗在美国溃疡性结肠炎患者中的真实世界疗效。
Curr Med Res Opin. 2025 Apr;41(4):683-689. doi: 10.1080/03007995.2025.2494642. Epub 2025 May 6.
5
Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.接受依奇珠单抗或乌司奴单抗治疗的银屑病患者早期应答与长期稳定应答相关。
J Drugs Dermatol. 2022 Feb 1;21(2):122-126. doi: 10.36849/jdd.6063.
6
Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review.比较美国、欧洲和英国乌司奴单抗治疗银屑病的指南：批判性评估和全面综述。
Dermatol Ther. 2021 Jul;34(4):e14974. doi: 10.1111/dth.14974. Epub 2021 May 22.
7
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.在生物暴露程度高的炎症性肠病患者中使用维持性静脉注射优特克单抗优化治疗结果。真实世界中的疗效和调整方案。
Gastroenterol Hepatol. 2025 May;48(5):502253. doi: 10.1016/j.gastrohep.2024.502253. Epub 2024 Sep 11.
8
Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.阿达木单抗、戈利木单抗或乌司奴单抗在炎症性肠病中的剂量递增：现实临床实践中的特征及意义
Scand J Gastroenterol. 2022 Apr;57(4):415-423. doi: 10.1080/00365521.2021.2014950. Epub 2021 Dec 19.
9
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.系统评价和荟萃分析：血清乌司奴单抗浓度与炎症性肠病治疗反应的关系。
Inflamm Bowel Dis. 2024 Apr 3;30(4):660-670. doi: 10.1093/ibd/izad065.
10
Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.在日常临床实践中比较阿达木单抗、依那西普和乌司奴单抗治疗银屑病患者的 1 年和 5 年疗效：来自前瞻性 BioCAPTURE 登记研究的结果。
Br J Dermatol. 2017 Apr;176(4):1001-1009. doi: 10.1111/bjd.15023. Epub 2017 Mar 10.